<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450579</url>
  </required_header>
  <id_info>
    <org_study_id>7373-CL-0106</org_study_id>
    <nct_id>NCT01450579</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Immune Response to the ASP7373 and Its Safety in Healthy Adult Volunteers</brief_title>
  <official_title>Phase II Study of ASP7373 Evaluation of Immunogenicity and Safety of ASP7373 in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMN Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMN Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is to investigate the clinically recommended dosage for ASP7373 based on the
      comparison of the immunogenicity and safety among the three doses of ASP7373 in healthy
      adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessed by the incidence of adverse events, vital signs, laboratory tests and 12-lead ECGs</measure>
    <time_frame>up to 43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity (HI antibody titer)- first vaccine</measure>
    <time_frame>on Day 21</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Immunogenicity (HI antibody titer)- second vaccine</measure>
    <time_frame>on Day 43</time_frame>
    <description>second vaccination on Day 22</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP7373</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose -2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP7373</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose -3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASP7373</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ASP7373</intervention_name>
    <description>Intermuscular administration</description>
    <arm_group_label>Dose -1</arm_group_label>
    <arm_group_label>Dose -2</arm_group_label>
    <arm_group_label>Dose -3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular administration</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight: Female: ≥40.0 kg, &lt;70.0 kg, Male: ≥50.0 kg, &lt;80.0 kg

          -  BMI: ≥17.6, &lt;26.4

          -  Healthy, as judged by the investigator or sub-investigator based on the results of
             physical examinations (subjective symptoms and objective findings) and all tests
             obtained

        Exclusion Criteria:

          -  Scheduled to receive another vaccine during study period

          -  History of H5 influenza infection or received H5 influenza vaccine

          -  Past history of anaphylactic shock or an allergic reaction such as generalized
             eruption due to food or drug (including vaccines) allergies, fever ≥ 39.0°C within 2
             days after the previous vaccination (influenza vaccine and others)

          -  Diagnosis of immune deficit in the past, has a family member (within the third degree
             of kinship) with a diagnosis of congenital immunodeficiency syndrome

          -  Received or scheduled to receive a live vaccine within 28 days prior to vaccination of
             the study vaccine, and received or scheduled to receive an inactivated vaccine or a
             toxoid within 7 days prior to vaccination of the study vaccine

          -  History of seizures

          -  Female subjects who are breastfeeding, pregnant, possibly pregnant, and planning to
             become pregnant during the study period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Use Central Contact</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kyushu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <last_update_submitted>September 27, 2017</last_update_submitted>
  <last_update_submitted_qc>September 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Recombinant Influenza HA vaccine</keyword>
  <keyword>Immunogenicity of ASP7373</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

